The Prevalence and Management of Saliva Problems in Motor Neuron Disease: A 4-Year Analysis of the Scottish Motor Neuron Disease Register.


Journal

Neuro-degenerative diseases
ISSN: 1660-2862
Titre abrégé: Neurodegener Dis
Pays: Switzerland
ID NLM: 101189034

Informations de publication

Date de publication:
2020
Historique:
received: 11 09 2020
accepted: 28 12 2020
pubmed: 27 4 2021
medline: 29 10 2021
entrez: 26 4 2021
Statut: ppublish

Résumé

Saliva problems are common and distressing for people with motor neuron disease (pwMND). Despite clinical guidelines for assessment and treatment, management of saliva problems has received little research attention. We aimed to investigate the prevalence of saliva problems in pwMND, their association with clinical factors, and their management practice using a highly curated population-based register for motor neuron disease (MND) with 99% case ascertainment. We conducted an analysis of pwMND diagnosed between January 2015 and October 2019 using the Scottish MND Register (CARE-MND [Clinical, Audit, Research, and Evaluation of MND]). The association between clinical factors and saliva problems was investigated using univariate and multivariable logistic regression; results are reported as odds ratio (OR) and 95% confidence intervals. A survey of health-care professionals involved in the care of pwMND was performed to contextualize the findings. 939 pwMND were included. Prevalence of saliva problems was 31.3% (294). Bulbar onset (OR 9.46 [4.7, 19.2]; p < 0.001) but not age, sex, time to diagnosis, or MND subtype were independently associated with the presence of saliva problems in multivariable regression, and 52.7% (155) of those with saliva problems received pharmacological management. The most commonly used medications were hyoscine, amitriptyline, carbocisteine, glycopyrrolate, and atropine. Evidence base (8, 72.7%) and local guidelines (10, 90.9%) were cited as the most important factors influencing treatment decision by survey respondents (n = 11). Saliva problems are common and associated with bulbar onset MND. A substantial proportion of pwMND with saliva problems did not receive recommended treatments. Future research is required to determine the relative efficacy of individual pharmacological treatments.

Identifiants

pubmed: 33902047
pii: 000514615
doi: 10.1159/000514615
pmc: PMC7610776
mid: EMS123326
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

147-152

Subventions

Organisme : Motor Neurone Disease Association
ID : MEHTA/JUL17/948-795
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R001162/1
Pays : United Kingdom

Informations de copyright

© 2021 S. Karger AG, Basel.

Références

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):521-7
pubmed: 23647474
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):21-28
pubmed: 29037065
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):589-95
pubmed: 24411632
J Neurol Sci. 1999 Oct 31;169(1-2):13-21
pubmed: 10540002
Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):198-205
pubmed: 26824413
Neurology. 2001 Aug 14;57(3):500-4
pubmed: 11502920
Ther Adv Neurol Disord. 2019 Nov 28;12:1756286419888601
pubmed: 31819763
J Neurol Sci. 2011 Sep 15;308(1-2):155-7
pubmed: 21726879
Muscle Nerve. 2012 Mar;45(3):311-8
pubmed: 22334165
Degener Neurol Neuromuscul Dis. 2019 Mar 20;9:19-26
pubmed: 31118868
J Neurol. 2019 Apr;266(4):817-825
pubmed: 30805795
Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):302-7
pubmed: 23134507
Acta Neurol Scand. 2016 Sep;134(3):224-31
pubmed: 26803950

Auteurs

Iona Pearson (I)

College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.

Stella A Glasmacher (SA)

Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.

Judith Newton (J)

Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.
Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom.

Emily Beswick (E)

Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.
Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom.

Arpan R Mehta (AR)

Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.
Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom.
Department of Clinical Neurosciences, NHS Lothian, Edinburgh, United Kingdom.

Richard Davenport (R)

Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.
Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom.
Department of Clinical Neurosciences, NHS Lothian, Edinburgh, United Kingdom.

Siddharthan Chandran (S)

Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.
Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom.
Department of Clinical Neurosciences, NHS Lothian, Edinburgh, United Kingdom.
UK Dementia Research Institute at University of Edinburgh, Edinburgh, United Kingdom.

Suvankar Pal (S)

Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.
Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom.
Department of Clinical Neurosciences, NHS Lothian, Edinburgh, United Kingdom.
Department of Neurology, NHS Forth Valley, Larbert, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH